A new study from The Hospital for Sick Children (SickKids) reveals the process underlying protein organization on cell ...

A new study from The Hospital for Sick Children (SickKids) reveals the process underlying protein organization on cell membranes, a finding which ...

Liver fibrosis is a major global health concern, developing as a result of chronic liver diseases (CLDs) such as viral ...

A phase 3 trial for myelofibrosis found that adding pelebresib to ruxolitinib was more effective than ruxolitinib alone and ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...

SINGAPORE: A new study from Duke-NUS Medical School has identified a promising new avenue for tackling pulmonary fibrosis, a ...

Learn about idiopathic pulmonary fibrosis, its symptoms, diagnosis, and treatment options for managing this lung disease.

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...

The global idiopathic pulmonary fibrosis market size was valued at USD 4.54 billion in 2024 and is projected to reach from ...

The global liver fibrosis treatment market is poised for substantial growth, with revenue projections increasing from USD 17.51 billion in 2024 to USD 51.16 billion by 2033. This expansion represents ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board (DSMB), as well as a ...